HighTower Advisors
RPRX icon

HighTower Advisors’s Royalty Pharma RPRX Stock Holding History

HighTower Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-5,000
Closed -$1.13K – 3945
2023
Q4 		$1.13K Buy
5,000
+4,990
+49,900% +$137K ﹤0.01% 3535
2023
Q3 		$2 Sell
10
-110
-92% -$3.27K ﹤0.01% 3557
2023
Q2 		$7.4K Buy
+120
New +$4.06K ﹤0.01% 3321

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HighTower Advisors's RPRX Position: Q2 2026 in Review

HighTower Advisors reduced its Royalty Pharma (RPRX) stake by 2.5% in Q2 2026, selling an estimated $379K and leaving 285,630 shares worth $16M. The position accounts for 0.02% of the portfolio, ranked #734.

HighTower Advisors first reported a position in RPRX in Q2 2021 and has held it in 21 quarters since. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • HighTower Advisors held 285,630 shares of Royalty Pharma worth $16M as of Q2 2026.
  • HighTower Advisors sold 7,291 Royalty Pharma shares in Q2 2026, an estimated $379K.
  • Royalty Pharma made up 0.02% of HighTower Advisors's portfolio in Q2 2026, its #734 holding.
  • HighTower Advisors first reported a position in Royalty Pharma in Q2 2021 and has held it in 21 quarters since.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.